This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
The combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration would be expected following a reduction in tumor vasculature after antiangiogenic treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
39
The use of the FDA approved drug sunitinib, used in an "off-label" manner with external beam radiation therapy.
Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
To evaluate the safety and toxicity profile of sunitinib when used with concurrent radiation therapy
The purpose of this study is to determine the safety of the combination of the antiangiogenic, sunitinib, when combined with external beam radiotherapy.
Time frame: 2 years
To measure urine VEGF
Urine VEGF may be a biomarker of response. This translational approach may be useful to determine who benefits from treatment.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.